ライフサイエンスコーパス: xenograft

1 erexpressing H441 non-small cell lung cancer xenograft.

2 th survivin siRNA, inhibited prostate cancer xenograft.

3 educed primate immune response in pig kidney xenograft.

4 alize the tumor in male mice bearing a SKOV3 xenograft.

5 ivation was also seen in a colorectal cancer xenograft.

6 [Y881F] is severely attenuated in human skin xenografts.

7 iferation in vitro, as well as in orthotopic xenografts.

8 pedestals were demonstrated in all infected xenografts.

9 ssion), or Calu-1 (no HER3 expression) tumor xenografts.

10 pe (p < 0.001) and drug-resistant (p < 0.05) xenografts.

11 ration both in vitro and in vivo as leukemia xenografts.

12 egression of all treated A2780 ovarian tumor xenografts.

13 owth in vivo, including TNBC patient-derived xenografts.

14 gnificantly prolonged survival in murine AML xenografts.

15 llular carcinoma cells in vitro and in mouse xenografts.

16 s retained abnormal SHH signaling like tumor xenografts.

17 vastatin caused regression of Ovcar-4 tumour xenografts.

18 reduction in the growth of MDA-MB-231 tumor xenografts.

19 s in approximately 50% of infected human gut xenografts.

20 sitive CWR22Rv1 and PSMA-negative PC-3 tumor xenografts.

21 combinations tested in patient-derived tumor xenografts.

22 ctal cancer cells in vitro and in vivo tumor xenografts.

23 gnancies and of human colorectal cancer cell xenografts.

24 l compared with untreated GSCs in orthotopic xenografts.

25 in KRAS(MUT) colorectal and pancreatic tumor xenografts.

26 th in HT-29 and SW480 cells and in nude mice xenografts.

27 ll migration and reduced the growth of tumor xenografts.

28 Multimodality imaging was performed in AR42J xenografts.

29 combined immunodeficiency mice bearing PC-3 xenografts.

30 asis of intravenous and intraprostatic tumor xenografts.

31 treatment of cells from PPR patient-derived xenografts.

32 d macrophages and the growth of colon cancer xenografts.

33 tumors in nude mice bearing dual-flank tumor xenografts.

34 er cells as well as impaired growth of tumor xenografts.

35 th in cell culture and mouse rhadomyosarcoma xenografts.

36 as in HDM201-resistant patient-derived tumor xenografts.

37 e bearing subcutaneous GPA33-positive SW1222 xenografts.

38 s and 15 models of cell- and patient-derived xenografts.

39 patient-derived GD2-expressing neuroblastoma xenografts.

40 rine and glycine can reduce tumour growth in xenograft and allograft models.

41 ivation but infiltrated a Burkitt's lymphoma xenograft and efficiently inhibited tumor growth followi

42 In xenograft and genetically engineered mouse models, the W

43 Moreover, SOX11(+) xenograft and human primary MCL tumors overexpress cell

44 phages infiltrate a human Burkitt's lymphoma xenograft and inhibit tumor growth, generating complete

45 s of lung cancer, including orthotopic human xenograft and Kras(LSL/G12D) mouse models of lung cancer

46 nhibited tumor growth and cancer invasion in xenograft and orthotopic mouse models, respectively.

47 f OTUD1 increases metastasis in intracardial xenograft and orthotopic transplantation models, and cor

48 toxicity and potent activity in both murine xenograft and patient-derived breast tumor explant model

49 results were confirmed in various cell line xenograft and patient-derived xenograft mouse models in

50 metastasis to the lung and liver in multiple xenograft and syngeneic mouse models.

51 cell lung cancers, including patient-derived xenograft and the genetically engineered mutant KRAS-dri

52 ar zinc levels in benign prostate cells, PCa xenografts and fresh prostate epithelial organoids.

53 ly suppresses development of intraperitoneal xenografts and prolongs the survival of ovarian cancer-b

54 Long-term growth in serial xenografts and spheroids was driven by multiple genomic

55 le clonogens in some SiHa cervical carcinoma xenografts, and in combination with gemcitabine using a

56 c cancer cell lines, primary patient-derived xenografts, and pancreatic controls and revealed strikin

57 The xenograft animal study demonstrated MART-10 could effect

58 on of subcutaneous and orthotopic SCLC tumor xenografts as well as distant organ metastases with high

59 oietic precursors, and show effectiveness in xenograft assays in mice.

60 Compared with orthotopic xenograft assays, the novel biomaterial cultures we deve

61 otocol to produce orthotopic patient-derived xenografts at diagnosis, recurrence, and autopsy.

62 drogens modify androgen signaling in CR-VCaP xenografts at multiple levels.

63 PC-3 tumor-xenografted BALB/c nu/nu mice were injected with either

64 L) and diffuse large B-cell lymphoma (DLBCL) xenografts blocked tumor growth, both when delivered in

65 e sites using flapless surgery combined with xenograft blocks provided complete formation of the bucc

66 its tumor growth in vivo using an orthotopic xenograft breast mouse model.

67 3D triple-negative cultures and intraductal xenografts by sustaining expression of E-cadherin and in

68 genesis on rigid substrates, with pretreated xenografts calcifying in vivo to a similar extent as nat

69 ally over an hour in a large volume of mouse xenograft colon tumor, and 3) determine the impact of th

70 nted macrophage and antibody response toward xenografts compared with allografts.

71 ne responses to neonatal porcine islet (NPI) xenografts compared with rhesus islet allografts at 1 ho

72 r, our results suggest that zebrafish larvae xenografts constitute a promising fast assay for precisi

73 dency, experiments in cell culture and mouse xenografts demonstrated that inhibition of CHK1 selectiv

74 plete and durable responses in neuroblastoma xenografts derived from these cells.

75 ion-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1

76 irmed by sequence polymorphisms within human xenograft-derived CTCs in mouse models.

77 ls showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f

78 neuroblastoma cell lines and patient-derived xenografts engraft and adopt a metastatic program in chi

79 reast tumor growth in ERalpha-negative mouse xenografts, especially when combined with TAM treatment.

80 ly grown castration-resistant VCaP (CR-VCaP) xenografts express high levels of AR and retain intratum

81 Xenografts expressing MIF-shRNA grew more rapidly with g

82 observed on the growth of HepG2 cell-derived xenografts expressing SLC13A5-shRNA in nude mice.

83 2 knockout blocks HCT-116 colon cancer tumor xenograft formation.

84 timize ChIP-Seq protocols on patient-derived xenografts from human papillomavirus-related (HPV(+)) he

85 organs with CHC may benefit post-transplant xenograft function.

86 vasive characteristics in vitro and suppress xenograft growth in mice.

87 c mice and MYCN gene-amplified neuroblastoma xenograft growth in nude mice.

88 enic capacity in vitro, and suppressed tumor xenograft growth in severe combined immunodeficiency mic

89 er cells, repressed colon CSCs and prevented xenograft growth.

90 mour microenvironment and robustly block HGG xenograft growth.

91 primary and secondary tumor formation using xenograft HEC1A models was determined.

92 e per gram [%ID/g]), whereas uptake in MKN45 xenografts (HGF-negative) was 5.0 +/- 1.3 %ID/g and a co

93 DFO-AMG102 at 120 h after injection in U87MG xenografts (HGF-positive) was high (36.8 +/- 7.8 percent

94 ers to identify radioresistant breast cancer xenografts highly amenable to sensitization by cotreatme

95 Different bladder cancer xenografts, however, demonstrate differential sensitivit

96 ppresses the growth of human colon carcinoma xenograft in nude mice in an RXRalpha-dependent manner.

97 ncer cells in vitro and cervical cancer cell xenograft in vivo in nude mice, and suppress cervical ca

98 7-[(18)F]FTrp accumulated in different tumor xenografts in a chick embryo CAM model.

99 colonized tenascin-C-coated trabecular bone xenografts in a novel system that employed chorioallanto

100 etect alphavbeta3 integrin in human melanoma xenografts in a selective fashion.

101 Insulinoma xenografts in carbidopa-treated mice showed significantl

102 s well as growth rates of BCSC-derived tumor xenografts in immunodeficient mice.

103 using human cancer cells and patient-derived xenografts in mice, we show that the cyclin D3-CDK6 kina

104 astatin induces regression of ovarian cancer xenografts in mice.

105 n potent activity in cell cultures and tumor xenografts in mice.

106 growth of WT and mutant ER-expressing tumor xenografts in NOD/SCID-gamma mice after oral or subcutan

107 as signaling and diminishes tumorigenesis of xenografts in nude mice.

108 IVIS spectrum imaging also visualized PC-3 xenografts in vivo and ex vivo with a high-contrast rati

109 ation in vitro and inhibited growth of tumor xenografts in vivo.

110 vitro and enhanced clearance of PD-L1+ tumor xenografts in vivo.

111 of decorin for treatment of breast carcinoma xenografts induces paternally expressed gene 3 (Peg3), a

112 ctor 1alpha (HIF-1alpha) expression in HT-29 xenografts initiated from NOX1 knockdown cells.

113 ophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and

114 erapy in treating mice with intracranial GBM xenograft markedly slows tumor growth and provides a sig

115 egative, MET-positive) and 4 patient-derived xenografts (MET-positive, HGF unknown).

116 evels (p<0.05) in mice bearing ectopic human xenograft MIA PaCa-2 pancreatic tumours with an average

117 on in the leukemic burden in patient-derived xenograft mice.

118 o significantly slowed tumor growth in DLBCL xenograft mice.

119 Finally, by treatment of UCS-xenografted mice with miR-200c incorporated in DOPC nano

120 d lengthening the survival of intracranially xenografted mice.

121 in significantly improved survival rates in xenografted mice.

122 ion of ODZ1 in GBM cells reduced survival of xenografted mice.

123 uptake in PSMA-positive tissues in the LNCaP xenograft model (1 h after injection).

124 formed phenotype, it slows tumor growth in a xenograft model and correlates with prolonged survival i

125 e imaged using (68)Ga-PSMA-11 PET in a mouse xenograft model and in a patient with castration-sensiti

126 he expression of WASF3 and Arp2/3 in a mouse xenograft model and reduces metastasis.

127 umors and lung metastases in a breast cancer xenograft model as well as extravasation following injec

128 toyltransferase IA in an AML patient-derived xenograft model improves survival.

129 When evaluated for the efficacy in A549 xenograft model in mice, both the liposomes demonstrated

130 e in insulinoma beta-cells and an insulinoma xenograft model in mice.

131 medullary myeloma manifestations in a murine xenograft model in vivo.

132 ooperative antitumor activity in lung cancer xenograft model in vivo.

133 We validated our results in a xenograft model in which we observed an increase in surv

134 In a mouse xenograft model insensitive to trastuzumab, coadministra

135 d animal survival to >90 days in a cell-line xenograft model of disseminated ovarian cancer.

136 more likely by systemic insults, a humanized xenograft model of FSGS resulted in an expansion of Gr-1

137 In a murine xenograft model of glioblastoma, whereas temozolomide on

138 ld effectively trigger tumor regression in a xenograft model of HCC.

139 g was sufficient to reduce tumor growth in a xenograft model of HNSCC.

140 We established a mouse xenograft model of human acute myeloid leukemia (AML) th

141 s paralogue TCF7L2 reduces tumor growth in a xenograft model of human skin SCC.

142 from both human cancer cell lines and mouse xenograft model showed that cancer cells carrying the un

143 Human MM xenograft model studies demonstrate that OPA treatment r

144 We found that cimetidine treatment in a xenograft model using A549 lung adenocarcinoma cells res

145 se-expressing ES-2 (ES-2-luc) ovarian cancer xenograft model, single i.p. injections of g-E and g-EAR

146 Using a xenograft model, we found that 3-aminopyridine-2-carboxa

147 vitro and attenuates tumor growth in a mouse xenograft model.

148 antileukemic activity in vivo in a leukemia xenograft model.

149 ontrolled leukemia cells in vivo in a murine xenograft model.

150 thotopically induced colorectal cancer (CRC) xenograft model.

151 shows durable tumor regression in a lymphoma xenograft model.

152 delayed tumor growth in a radiation-treated xenograft model.

153 ell lines (TMD and BMD) derived from a mouse xenograft model.

154 moate is further confirmed in a subcutaneous xenograft model.

155 utic agents in vitro and in vivo in a murine xenograft model.

156 proliferation in tumor cell lines and a rat xenograft model.

157 lpha 1 chain) genes, and in an in vivo tumor xenograft model.

158 cy of THIQ 40 in a MCF-7 human breast cancer xenograft model.

159 efficacy in an ES-2-luc, ovarian cancer i.p. xenograft model.

160 n AML cells blocks leukemia progression in a xenograft model.

161 effectively reduced tumor growth in a mouse xenograft model.

162 mor growth inhibition of the CW22Rv1 in vivo xenograft model.

163 ds was also demonstrated in a human melanoma xenograft model.

164 selective, and efficacious in a KRAS mutant xenograft model.

165 impaired tumor clearance in a sub-cutaneous xenograft model.

166 n assay, transwell invasion assay, and tumor xenograft model.

167 ffectively inhibited B-ALL growth in a human xenograft model.

168 or efficacy and toxicity using a mouse SW620 xenograft model.

169 splays efficacy in a human ovarian carcinoma xenograft model.

170 axel based chemotherapies in patient-derived xenograft models (PDX) with RSPO3 fusions and in tumors

171 arcinoma cells to drug-induced cell death in xenograft models and ex vivo cultures.

172 delayed tumor growth in all rodent pediatric xenograft models and extended animal survival while demo

173 s, and prolonged survival in both orthotopic xenograft models and mouse models of primary AML.

174 Using transgenic and xenograft models and tunable two- and three-dimensional

175 We treated 10 childhood ALL patient-derived xenograft models harboring various Ph-like genomic alter

176 elastic modulus in colorectal adenocarcinoma xenograft models in vivo and investigate any correlation

177 of aneuploidy, and genetic heterogeneity in xenograft models likely through modulation of Wnt signal

178 in AR variants-expressing CRPC cell line and xenograft models markedly reduces tumor growth through i

179 In xenograft models of EOC using SKOV3ip1 or HeyA8, mice tr

180 In intracranial mouse xenograft models of glioblastoma, inhibiting Wnt5a activ

181 was therapeutically effective against mouse xenograft models of human leukemia.

182 netically engineered mouse models and murine xenograft models of human MIBC, we demonstrate that tumo

183 enesis in subcutaneous and intrabursal mouse xenograft models of human ovarian cancer.

184 In mouse xenograft models of human TNBC, administration of C1572

185 In orthotopic xenograft models of pancreatic cancer, combining PDP wit

186 n 4 different gastric cancer patient-derived xenograft models showed low uptake of (89)Zr-DFO-AMG102

187 Xenograft models showed that the lung extravasation and

188 atin ADCs imparted activity in cell line and xenograft models that are refractory to ADCs comprised o

189 In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an on

190 In vivo tumor-targeted uptake in mouse xenograft models using (124)I-CLR1404 was confirmed by i

191 vitro and led to tumor growth regression in xenograft models with a KRAS, NRAS or BRAF mutation at t

192 roblast (CAF)-derived EVs (from patients and xenograft models) laden with whole genomic mtDNA as a me

193 cers, facilitation of tumor growth in murine xenograft models, and centrosomal amplification induced

194 Moreover, in two distinct tumor xenograft models, combined delivery of ICOVIR-15K-cBiTE

195 cancer cells and polyclonal patient-derived xenograft models, including tumours resistant to PARP in

196 Using xenograft models, we showed that chronic behavioral stre

197 than wild-type clones in s.c. and orthotopic xenograft models.

198 umor activity in mouse Her2(2+) and Her2(1+) xenograft models.

199 or growth inhibition efficacy in mouse flank xenograft models.

200 potential of (131)I-CLR1404 was evaluated in xenograft models.

201 proteogenomic response predictions in seven xenograft models.

202 n (Doxil) in HER2-overexpressing BT474 tumor xenograft models.

203 y in MCL patient samples and patient-derived xenograft models.

204 SMA uptake increased 1.5- to 2.0-fold in the xenograft mouse model after treatment with both orchiect

205 We confirmed using a human-derived tumor xenograft mouse model that bicalutamide pre-treatment is

206 This orthotopic xenograft mouse model will enable clinically relevant te

207 ited the growth of MGC803 cells in vivo in a xenograft mouse model without observed toxicity.

208 In a TNBC xenograft mouse model, JNK-IN-8 significantly suppressed

209 nd in vivo antitumor effects in a MIA PaCa-2 xenograft mouse model.

210 , as well as animal survival rate in a HT-29 xenograft mouse model.

211 and in vivo significance was assessed via a xenograft mouse model.

212 d kinetics of (18)F-FETrp in patient-derived xenograft mouse models and compared them with (11)C-AMT

213 improved ovarian cancer treatment in SKOV-3 xenograft mouse models in comparison with free drugs and

214 ious cell line xenograft and patient-derived xenograft mouse models in vivo.

215 median survival in two patient-derived BTIC xenograft mouse models of GBM.

216 Xenograft mouse models of glioblastoma and metastatic br

217 he knockdown of LAMB1 or K19 in subcutaneous xenograft mouse models resulted in significant loss of c

218 K46N increased lung metastases in MDA-MB-231 xenograft mouse models.

219 ces apoptosis and cell death in vitro and in xenograft mouse models.

220 human NSCLC tumour samples, patient-derived xenografts, murine model of NSCLC, NSCLC cell lines and

221 ss H1299 lung cancer tumor growth in a mouse xenograft NOD-SCIDgamma model.

222 cancer cells and suppresses deformations of xenograft nuclei in vivo.

223 , resulting in aggressive tumor formation in xenograft nude mice, which could be suppressed by combin

224 ution properties, SPECT and CT scans of HT29-xenografted nude mice injected with (177)Lu-3BP-227 were

225 oblastoma specimens and in orthotopic murine xenografts of human BTIC implanted intracranially.

226 tting-in several nonprostatic cell lines and xenografts of melanoma and small cell lung cancer (SCLC)

227 Orthotopic xenografts of MKN45/5FU cells in the stomach of nude mic

228 U dose, and in gastric submucosal orthotopic xenografts of MKN45/5FU cells.

229 ution studies were performed in mice bearing xenografts of the same cell lines, comparing (68)Ga-THP-

230 F ELISA experiments were performed on murine xenografts of U87MG (HGF-positive, MET-positive) and MKN

231 ted in increased metastatic dissemination in xenograft or syngeneic tumor models in vivo.

232 Finally, we generated patient-derived xenograft (PDX) models from patient-derived HTR bone met

233 was applied to a panel of 12 patient-derived xenograft (PDX) models of glioblastoma to predict gliobl

234 sion across 24 breast cancer patient-derived xenograft (PDX) models.

235 ssion, we used two different patient-derived xenograft (PDX) models: Patient 17(CXCR4-low) and P15(CX

236 n breast cancer patients and patient-derived xenograft (PDX) samples to predict pathway activity, and

237 reast cancer, and patient-derived orthotopic xenografts (PDX) of human glioblastoma.

238 Patient-derived xenografts (PDX) of pediatric mixed-lineage leukemia gen

239 Patient-derived xenografts (PDXs) are a reliable preclinical model that

240 atient avatars; for example, patient-derived xenografts (PDXs) established in mice and used for drug

241 Patient-derived xenografts (PDXs) have become a prominent cancer model s

242 ncogene (BRAF(amp)) in patient-derived tumor xenografts (PDXs) that were treated with a direct inhibi

243 one metastasis specimens and patient-derived xenografts (PDXs) were found to co-express endothelial m

244 Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK expression whi

245 ation in human MDA-MB-231 mammary tumor cell xenografts reduced the sizes of both the primary tumor a

246 inhibitors to orthotopic AML patient-derived xenografts reduced tumor burden and prolonged overall su

247 o mice engrafted with a PTCL patient-derived xenograft resulted in a shift among tumor-associated mac

248 nally, treatment of mice bearing GSC-derived xenografts resulted in significant inhibition of tumor p

249 ing a human cancer cell line panel and mouse xenografts revealed that 6OTD exhibits antitumor activit

250 earing contralateral flank UM-UC-3 and RT112 xenografts selectively arrested tumor growth in UM-UC-3

251 SN12 tumor xenografts showed decreased growth when treated with CB-

252 HepG2 and Huh-6 xenografts showed expression of beta-catenin, AFP, and G

253 ts p5365-73 peptide-expressing breast cancer xenografts, significantly inhibiting tumor growth.

254 older than 10-12 GW, or in second trimester xenografted testes (14-17 GW).

255 kedly prolonged survival of donor swine skin xenografts that may be applicable to clinical solid orga

256 One patient-derived xenograft, the estrogen receptor-positive model T126, wa

257 ce in vivo using a series of patient-derived xenografts to generate paired chemosensitive and chemore

258 of the antiangiogenic response of 786-0 RCC xenografts to sunitinib, which revealed that pretreatmen

259 Porcine-NICC xenograft tolerance was abrogated after depletion of Fox

260 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the op

261 ation and cell migration in vitro as well as xenograft tumor growth and metastasis in an orthotopic m

262 nks of severe combined immunodeficient mice; xenograft tumor growth and metastasis were assessed.

263 C cell proliferation in vitro and to abolish xenograft tumor growth in vivo Taken together, our findi

264 BRAF mutant cell proliferation in vitro and xenograft tumor growth in vivo.

265 Activated form of Notch1 promotes xenograft tumor growth when expressed ectopically.

266 in a set of patient-derived prostate cancer xenograft tumor lines, we identified miR-100-5p as one o

267 uman PTEN-deficient LNCaP prostate carcinoma xenograft tumor model.

268 nd the tumor growth were verified in vivo by xenograft tumor studies.

269 FLT uptake were also observed for MDA-MB-231 xenografts (tumor-to-muscle ratio, 7.2 +/- 0.9 for femal

270 an breast carcinoma and IHC analysis of mice xenograft tumors demonstrated that DACH1 inversely relat

271 Xenograft tumors from colon tumor cells with O-linked N-

272 tor canertinib; these drugs slowed growth of xenograft tumors from MAN2A1-FER cells and prevented the

273 EAC patient-derived xenograft tumors grew more slowly in mice given the comb

274 g) liposome treatment revealed regression of xenograft tumors in both wild type (p < 0.001) and drug-

275 P90 inhibitors, in culture and when grown as xenograft tumors in mice, depended on expression of miRN

276 and invasiveness and formed larger (>2-fold) xenograft tumors in mice, with more metastases, than cel

277 ncer cell lines in vitro and on subcutaneous xenograft tumors in mice.

278 aP cells completely suppresses the growth of xenograft tumors in mice.

279 inhibitors; growth of these patient-derived xenograft tumors was quantified.

280 Mice bearing xenograft tumors were intraperitoneally treated with SB4

281 types, such as cell invasion, migration, and xenograft tumors, in nude mice.

282 ells with MAN2A1-FER knockout formed smaller xenograft tumors, with fewer metastases, than control HU

283 vironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per

284 Patient-derived xenograft tumours growing in immunodeficient mice exhibi

285 shes growth of cell line and patient-derived xenograft tumours in vivo.

286 The origins of the patient-derived xenograft tumours were reflected in their gene-expressio

287 Analyses of BITC-treated xenografts using LKB1-null cells corroborate in vitro me

288 ted NPs was evaluated in mice bearing LS174T-xenografts using magnetic resonance (MR) imaging and flu

289 13)Bi and (177)Lu for PRIT of CEA-expressing xenografts, using the bispecific monoclonal antibody TF2

290 highly diverse, clonal composition in serial xenografts was highly similar between recipients of the

291 observed complete eradication of solid tumor xenografts, we conclude that targeted alpha-therapy regi

292 jects bearing reporter-modified intracranial xenografts, we quantitatively assessed MGMT knockdown by

293 Regardless of carbidopa premedication, the xenografts were characterized by an early increase in (1

294 eukemia, we demonstrate that patient-derived xenografts were highly polyclonal, consisting of tens to

295 selectively arrested tumor growth in UM-UC-3 xenografts, which had reduced tumor size, reduced Ki-67,

296 Nude mice xenografted with the human NET cell line GOT1 were treat

297 ed venetoclax treatment of MCL and ABC-DLBCL xenografts with a pretargeted RIT (PRIT) system directed

298 as active against two enzalutamide-resistant xenografts with minimal toxicity.

299 e harboring platinum-resistant ovarian tumor xenografts with pHLIP-PNA constructs suppressed HOTAIR a

300 amples to generate zebrafish patient-derived xenografts (zPDX) and provide proof-of-concept experimen